Mammalian Cell cGMP Production Facility

EirGenix has a strong track record in mammalian cell biopharmaceuticals, with extensive experience using CHO K1, CHO S, and HEK293 cells to develop and produce fusion proteins, monoclonal antibodies, bispecific/trispecific antibodies, and antibody-drug conjugates. Our state-of-the-art cGMP production facilities in New Taipei City (Xizhi) and Zhubei, Taiwan, support this work. The Xizhi facility (~10,000 sq ft) includes 100 L and 500 L stainless steel bioreactors and 50 L, 200 L, and 1,000 L single-use bioreactors (SUB), along with purification, medium and buffer preparation, washer, and autoclave rooms. The Zhubei facility, operational since 2019, houses two 1,000 L and four 2,000 L SUB systems, providing twelve 2,000 L SUB units and enabling annual antibody production of up to 1,000 kg.